Efficacy and safety of bamlanivimab compared to standard care/placebo

The information presented in the summary of findings table below comes from a living network meta-analysis that combines all the available evidence on prophylactic interventions for COVID-19. This statistical approach allows us to obtain estimates of effect for all potential comparisons, even those that have not been compared head-to-head in trials. We present the most trustworthy estimates of effect, based on the GRADE approach.

Comparison of bamlanivimab to standard care/placebo:

Summary of Findings Table

Population: People at risk of COVID-19

Export to PDF
OutcomeN studies / participants with direct evidenceRelative effect estimatesAbsolute effect estimatesCertainty of the EvidencePlain language summarySource of highest certainty estimate
Mortality
(closest to 90 days)		1 RCTs;
966 patients		N/ADifference: 2 fewer per 1000
(95% CI 34 fewer to 30 more)		LOWDue to very serious imprecision, Bamlanivimab may reduce mortality compared to standard care/placeboNMA
Laboratory-confirmed SARS-CoV-2 infection1 RCTs;
966 patients		Odds Ratio: 0.58
(95% CI 0.23 - 1.42)		Difference: 24 fewer per 1000
(95% CI 50 fewer to 24 more)		LOWDue to very serious imprecision, Bamlanivimab may reduce laboratory-confirmed infection compared to standard care/placeboNMA
Suspected, probable, or laboratory-confirmed SARS-CoV-2 infection
No data were reported for this outcome.
Admission to hospital (within 28 days)
No data were reported for this outcome.
Adverse events leading to discontinuation (within 28 days)
No data were reported for this outcome.
Time to symptom(s) resolution (in days)
No data were reported for this outcome.

Abbreviations: AE, adverse events; 95% CI, 95% credible interval; NMA, network meta-analysis; N/A, not applicable; RCT, randomized control trial; SARS-CoV-2, severe acute respiratory syndrome–related coronavirus 2

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

    Questions or comments about the data you see on this page?

    ©2021 by COVID-19 Living Network Meta-Analysis Terms of Service